Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.

ABSTRACT:

Introduction

Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns.

Methods

We completed a retrospective review of US data (through May 2019) from the IBM MarketScan^® Early View Databases, identifying adult patients newly treated with erenumab with a migraine claim in the year prior to first erenumab claim (index) and at least 1 year of continuous pre-index medical and pharmacy insurance coverage, to assess pre- and post-erenumab migraine characteristics, comorbidities, healthcare resource utilization, and associated costs. All data were summarized using descriptive statistics.

Results

A total of 9753

SUBMITTER: Chandler D 

PROVIDER: S-EPMC8586283 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature